Header image

Transforming Global Genetic Data into Medical Decisions

Our goal is the rapid medical diagnosis of inherited diseases, provided at the earliest possible moment as we turn analytical information into actionable results for physicians, patients and pharmaceutical partners.

Our commitment to the global medical community is an early and precise diagnosis for continuous improvement of therapeutic options for each individual patient.

Latest Scientific News

Prodromal substantia nigra sonography undermines suggested association…

Parkinson’s disease (PD) and Gaucher disease are amongst the primary research foci at…

Utility and implications of exome sequencing in early-onset Parkinson's…

Although the genetic load is high in early-onset Parkinson’s disease, thorough…

Development of an Evidence-Based Algorithm that Optimizes Sensitivity and…

Next-generation sequencing (NGS) is rapidly replacing Sanger sequencing in genetic…

Confirmation of ACER3-Related Recessive Neurodegeneration

Learn more about our recent findings in confirmation of ACER3-related recessive…

Customer Feedback

Give feedback

Newsletter subscription

CENTOGENE, a rare disease company committed to improving the lives of rare disease patients by providing solutions that accelerate the development of drugs, has...

Read more

Driving Pharmaceutical Partnerships and Accelerating Orphan Drug Development

Read more

CENTOGENE’s state-of-the-art genetic laboratory facilities in Rostock, Germany awarded accreditation for the fourth year

Read more

2018 highlights include expansion to U.S., new partnerships with leading pharmaceutical companies, and growth of diagnostic testing portfolio for rare diseases...

Read more

NORTHFIELD, IL. — The College of American Pathologists (CAP), a Center for Medicare and Medicaid Services (CMS)-approved accreditation authority, has awarded...

Read more

Provides physicians with virtual encyclopedia of genetic information at their fingertips for improved and efficient diagnosis of rare diseases

Read more

CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation...

Read more

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform

Read more

We are proud to have been honored with the award from the Federal State Government of Mecklenburg-Vorpommern in the category ‘Company Development’. We are...

Read more